Marksans Pharma Q2 PAT seen up 1133% to Rs 12.7 cr: Centrum

Net Sales are expected to increase by 12.4 percent Q-o-Q (down 17.8 percent Y-o-Y) to Rs 210 crore, according to Centrum.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney master your money IThe Winning Leap SME Special
Moneycontrol

Home » News » Earnings » Brokerage Results Estimates

Oct 19, 2016, 03.42 PM | Source: Moneycontrol.com

Marksans Pharma Q2 PAT seen up 1133% to Rs 12.7 cr: Centrum

Net Sales are expected to increase by 12.4 percent Q-o-Q (down 17.8 percent Y-o-Y) to Rs 210 crore, according to Centrum.

Like this story, share it with millions of investors on M3

Marksans Pharma Q2 PAT seen up 1133% to Rs 12.7 cr: Centrum

Net Sales are expected to increase by 12.4 percent Q-o-Q (down 17.8 percent Y-o-Y) to Rs 210 crore, according to Centrum.

Post Your Comments

Share Cancel

Centrum Broking (more)

, Centrum Broking |

Centrum has come out with its second quarter (July-September) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Marksans Pharma  to report net profit at Rs 12.7 crore, up 1133 percent quarter-on-quarter.

Net Sales are expected to increase by 12.4 percent Q-o-Q (down 17.8 percent Y-o-Y) to Rs 210 crore, according to Centrum.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 195.9 percent Q-o-Q (down 52.3 percent Y-o-Y) to Rs 24.5 crore.

Centrum's report on Marksans Pharma

We expect Marksans Pharma’s (MPL) revenue to decline by 18% YoY and grow by 12% QoQ to Rs2.10bn due to restrictive imports of company’s products in UK. MPL’s UK business (38% of revenues) is likely to decline by 28% YoY to Rs 790mn as the company has been permitted to export only critical products to the UK market.

The company’s US business (44% of revenues) is expected to decline by 19% YoY and grow by 17% QoQ due to integration of TCL during the year and commencement ofsupplies to Walgreen from Q1FY17. The company is set to report 64% YoY decline in net profit to Rs 127mn from Rs 349mn.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click here

Buy, Hold, Sell ? Hear it first on M3
Marksans Pharma Q2 PAT seen up 1133% to Rs 12.7 cr: Centrum

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login